According to incomplete statistics from Innovation Radar, last week (July 14 to July 20), the global pharmaceuticals and healthcare sectorA total of 23 financing events were disclosed, with a total financing amount exceeding 5.6 billion US dollars.。

Last week, a significant financing event occurred in the nuclear medicine field. On July 18,Yantai Lannacheng Biotechnology Co., Ltd. Announces Completion of Over 300 Million Yuan in C+ Round Financing, which will advance the clinical development of Radiopharmaceutical Drug Conjugates (RDC). The company's pipeline currently covers highly prevalent cancer types such as prostate cancer and gastric cancer. A total of 10 nuclear medicine products targeting four sites are in clinical trial stages in both China and the U.S.

In the cancer vaccine field, two companies have received financing.Chimigen Bio, which focuses on the development of therapeutic vaccines for cancer and viral infections, announced on the 18th the completion of a pre-A round of financing worth nearly 170 million yuan.The company, based on its self-developed vaccine platform, is committed to activating the immune response of "cold tumors" and breaking the immune tolerance of tumor cells again. The financing will accelerate the global clinical development of the prostate cancer therapeutic vaccine SN3001 and the chronic hepatitis B immunotherapy vaccine SN2001.

In addition,Japanese Oral Vaccine Development Company Immunorock Secures Over 180 Million Yen in Additional FundingThe company owns an oral vaccine platform technology based on the characteristics of bifidobacteria, and is committed to developing the oral cancer therapeutic vaccine B440, an oral bifidobacteria vector WT1 vaccine. A Phase 1 clinical trial targeting metastatic urothelial carcinoma was initiated in early 2023, and a Phase 1/2a clinical trial for malignant pleural mesothelioma will be launched in October this year.

Financing in the cell therapy field is also proceeding continuously.T Cell Immunotherapy Company Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd. Completes Nearly 40 Million USD in Series B FinancingIts CAR-T pipeline, TX-103, primarily targets solid tumors such as recurrent glioblastoma. The funds will advance the drug's clinical development in both China and the U.S.

In the CNS field,Illimis Therapeutics, a South Korean company, completes $42 million financing round with participation from over ten institutions, will advance the development of core pipeline ILM01 for the treatment of Alzheimer's disease. The company’s technology platform explores breakthrough potential therapeutic solutions by modulating the TAM (Tyro3/Axl/Mer) receptor biology pathway.

At the same time, other directions of innovative drug research and development are also proceeding steadily. In the field of small nucleic acids, Ribo Life Science announced that its subsidiaryRibo International Completes $33 Million Equity Financing；ADC Drug Development Company TriOar Completes Approximately $16 Million in Financing。

Readers, please star ⭐Chuangjianhui to receive updates第一时间.

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please consult a正规 hospital.

Copyright Statement: Welcome to share to Moments. Unauthorized media or institutions are prohibited from reprinting or copying in any form to other platforms. For reprint authorization, please contact"InnoView"Contact us via WeChat Official Account comments.

More Data Content Recommendations

Click "InSee", Sharing Chuangjian Hui Health New Trends